Mother of Two Enters Remission After TIL Cell Therapy for Stage 4 Melanoma

Published on Spencer Knight via LinkedIn

Missy Christy had already beaten cancer once. Then, as a new mother, she faced it again—this time as stage 4 melanoma. Immunotherapy failed. Surgery didn’t help. She was out of options.

In May 2024, Missy became one of the first patients to receive lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy developed by Iovance Biotherapeutics at Cleveland Clinic. Her own immune cells were multiplied in a lab and reinfused to precisely target her cancer.

Months later, the results are remarkable. Her tumors are shrinking. She’s off major medications, running again, and back to full-time parenting. Spencer Knight calls it a powerful glimpse of what the future of cancer care could look like.

Read the full article via News 5 Cleveland:

👉 Mother With Advanced Melanoma Sees Promising Results With Innovative Cellular Therapy

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.